Hematology/Oncology

Top Story

Subsequent metastases from prostate cancer increase treatment costs

July 21, 2017

Men with localized prostate cancer diagnosed with subsequent metastases experienced substantial cost increases for diagnostic, therapeutic and supportive care services during treatment, according to an observational cohort study published in Cancer.

“The development of metastases in patients initially diagnosed with localized prostate cancer is a seminal event of progression and results in excess morbidity, mortality and cost,” Robert I. Griffiths, MS, ScD, chief scientific officer at Boston Health Economics, and colleagues wrote.

In the Journals

Patient age associated with lymph node positivity in thin melanomas

July 21, 2017
Patient age was a factor in regional lymph node positivity in clinically localized melanomas 0.5 mm to 10 mm, according to recently published study results in JAMA
In the Journals Plus

Nivolumab, ipilimumab combination shows promise for renal cell carcinoma

July 21, 2017
Combination therapy with nivolumab and ipilimumab led to notable antitumor activity and durable response among patients with metastatic renal cell carcinoma, according…

CDC: Multicomponent interventions boost colorectal, breast, cervical cancer screening

July 21, 2017
Multicomponent interventions effectively increase colorectal cancer screening with colonoscopy or fecal occult blood testing, according to a CDC report. The CDC’s…
In the Journals Plus

Race, ethnicity impact use of autologous stem cell transplantation for multiple myeloma

July 21, 2017
Hispanic patients with multiple myeloma in the United States demonstrated the lowest usage rate for autologous hematopoietic stem cell transplantation, according to a…
More News Headlines »
CNE CME

The Identification and Management of Immune-related Adverse Events in Patients with Cancer: Practice Essentials for Emergency Medicine Providers

This activity is supported by an educational grant from Bristol-Myers Squibb.

The incorporation of immunotherapies, especially the immune checkpoint inhibitors, into treatment regimens for patients…
More »
Video
Meeting News

VIDEO: LATITUDE, STAMPEDE trials provide ‘practice-changing’ findings in prostate cancer

July 15, 2017
More »
Resource Centers
Biosimilars in the US

Biosimilars in the US

CME

Immune Checkpoint Inhibitors for Advanced Bladder Cancer: Applying Clinical Advances and Elucidating Best Practices

This activity is supported by an educational grant from Merck & Co, Inc.

Advances in immunology and the advent of immune checkpoint blockade inhibition for advanced bladder cancer are poised…
More »
Current Issues
View the Current Issue
HemOnc Today
Advertisement
Advertisement